Drug Watch

Latest News

FDA Approves Bimekizumab for Adults with Moderate to Severe HS
FDA Approves Bimekizumab for Adults with Moderate to Severe HS

November 20th 2024

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

Delgocitinib Approved for Adults with Moderate to Severe CHE in Switzerland
Delgocitinib Approved for Adults with Moderate to Severe CHE in Switzerland

November 14th 2024

FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa
FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa

November 12th 2024

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025
PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025

November 5th 2024

Video Interviews
Podcasts
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
The Cutaneous Connection

More News

© 2024 MJH Life Sciences

All rights reserved.